

GLOBUS MEDICAL INC  
Form 8-K  
March 01, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2019 (February 26, 2019)

GLOBUS MEDICAL, INC.  
(Exact name of registrant as specified in charter)

DELAWARE                      001-35621      04-3744954  
(State or other jurisdiction    (Commission    (IRS Employer  
of incorporation)              File Number) Identification No.)  
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403  
(Address of principal executive offices) (Zip Code)  
(610) 930-1800  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) On February 26, 2019, Anthony Williams, the Company's President, notified us that he has chosen to pursue opportunities outside of the Company. He will remain at the Company through May 31, 2019, working closely with the management team to ensure a seamless transition. Following Mr. Williams' departure, Dave Demski, the Company's Chief Executive Officer, will assume the role of President and Chief Executive Officer.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBUS MEDICAL, INC.  
(Registrant)

Dated: March 1, 2019 /s/ DANIEL T. SCAVILLA

Daniel T. Scavilla  
Executive Vice President  
Chief Financial Officer  
Chief Commercial Officer